NCT04891510 A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
| NCT ID | NCT04891510 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Weill Medical College of Cornell University |
| Condition | Mastectomy |
| Study Type | INTERVENTIONAL |
| Enrollment | 135 participants |
| Start Date | 2021-05-19 |
| Primary Completion | 2028-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 135 participants in total. It began in 2021-05-19 with a primary completion date of 2028-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to learn whether there is a superior fat processing method in terms of graft retention in breast reconstruction after mastectomy.
Eligibility Criteria
Inclusion Criteria: * Female; * Documented history of previous breast surgery (either complete or partial mastectomy); * Available harvest sites for fat grafting as documented by plastic surgeon; * BMI \> 20; * Anticipated harvested fat volume \> 50cc; * Competency and willingness to provide consent Exclusion Criteria: * Suspected or known to be pregnant
Contact & Investigator
David Otterburn, MD
PRINCIPAL INVESTIGATOR
Weill Medical College of Cornell University
Frequently Asked Questions
Who can join the NCT04891510 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Mastectomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04891510 currently recruiting?
Yes, NCT04891510 is actively recruiting participants. Contact the research team at mia7046@med.cornell.edu for enrollment information.
Where is the NCT04891510 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT04891510 clinical trial?
NCT04891510 is sponsored by Weill Medical College of Cornell University. The principal investigator is David Otterburn, MD at Weill Medical College of Cornell University. The trial plans to enroll 135 participants.